Skip to content
value.today

Hemoshear Therapeutics, Inc.

Total raised
$43 M
1 round on record
Latest round
$43 M
Feb 2021
First round on record
Feb 2021
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Hemoshear Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2021$43 MNo. 1$10 to $50 million

Hemoshear Therapeutics, Inc.: Raise no. 1, Feb 2021

Investors in this round

17 investors had bought by the notice of Feb 18, 2021: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$43 M of $48 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Offer and sale of Series A Preferred Stock, and the underlying shares of Common Stock issuable upon conversion thereof.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Aric R. Holsinger · Executive Officer
  • Brian A. Johns · Executive Officer
  • Brian Thomas Wamhoff · Executive Officer
  • James C. Powers · Executive Officer, Director
  • W. M. Thompson, Jr. · Executive Officer
  • David A. Friedman · Director
  • H. Thomas Watkins III · Director
  • John A. Tilton · Director
  • John L. Brooks · Director
  • Kathleen M. Metters · Director
  • Robert J. Gould · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total amount sold includes the value of cancelled indebtedness formerly held by certain purchasers in the aggregate principal and interest amount of approximately $3,102,069.37.”

Signed by Aric Holsinger, Chief Financial Officer. Newest notice filed Feb 18, 2021. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Hemoshear Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2021).

    SEC Form D · Feb 2021

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Feb 2021

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Hemoshear Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Hemoshear Therapeutics, Inc.
NameRoleNamed in
Aric R. HolsingerExecutive officerFeb 2021
Brian A. JohnsExecutive officerFeb 2021
Brian Thomas WamhoffExecutive officerFeb 2021
James C. PowersExecutive officerFeb 2021
W. M. Thompson, Jr.Executive officerFeb 2021
David A. FriedmanDirectorFeb 2021
H. Thomas Watkins IIIDirectorFeb 2021
James C. PowersDirectorFeb 2021
John A. TiltonDirectorFeb 2021
John L. BrooksDirectorFeb 2021
Kathleen M. MettersDirectorFeb 2021
Robert J. GouldDirectorFeb 2021